SUMMARY HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …

Abstract Introduction Proviral HIV DNA integrated within CD4 T-cells maintains an archive of
viral variants that replicate during the course of the infection, including variants with reduced …

Objective: We investigated the prevalence of preexisting M184V/I and associated risk factors
among clinical trial participants with suppressed HIV and evaluated the impact of M184V/I …

Methods: Retrospective review of treatment-experienced patients who started B/F/TAF in a
cohort of PWH. HIV-RNA less than 50 copies/ml was analyzed at 48 weeks in an intention-to …

Background Dual therapy combining integrase inhibitors and NNRTIs represents a
promising regimen in ageing HIV-infected individuals with long exposure to nucleoside …

Objectives Integrase resistance has not been reported with co-formulated dolutegravir/
lamivudine in clinical trials or real-life cohorts. We aim to report, to the best of our …

Background Maintenance ART with dolutegravir-based dual regimens have proved their
efficacy among HIV-1-infected subjects in randomized trials. However, real-life data are …

Patients with antiretroviral therapy interruption have a high risk of virological failure when re-
initiating antiretroviral therapy (ART), especially those with HIV drug resistance. Next …

Background We aimed to assess the kinetics of drug-resistant viral variants (DRVs)
harboring the M184V mutation in proviral DNA of long-term virally suppressed patients, and …

HIV evolution and variability around the world requires special monitoring of the viral strains
in infected people. High-throughput HIV sequencing and drug resistance testing techniques …